Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Author(s) -
Nadine Kronfli,
Jim Young,
Shouao Wang,
Joseph Cox,
Sharon Walmsley,
Mark Hull,
Curtis Cooper,
Valérie MartelLaferrière,
Alexander Wong,
Neora Pick,
Marina B. Klein,
Lisa Barrett,
Jeff Cohen,
Brian Conway,
Pierre Côté,
M. John Gill,
Shariq Haider,
Joan Montaner,
Erica E. M. Moodie,
Anita Rachlis,
Danielle Rouleau,
Roger Sandre,
Mark Tyndall,
Stephen Sanche,
Marie-Louise Vachon,
Alex Wong,
David Wong
Publication year - 2020
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa702
Subject(s) - medicine , coinfection , hepatitis c virus , transient elastography , gastroenterology , hepatitis c , hepatocellular carcinoma , liver biopsy , ribavirin , fibrosis , cohort , immunology , biopsy , virus
Noninvasive markers of liver fibrosis such as aspartate aminotransferase-to-platelet ratio (APRI) and transient elastography (TE) have largely replaced liver biopsy for staging hepatitis C virus (HCV). As there is little longitudinal data, we compared changes in these markers before and after sustained virologic response (SVR) in human immunodeficiency virus (HIV)-HCV coinfected patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom